Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa
Identifieur interne : 000493 ( Istex/Corpus ); précédent : 000492; suivant : 000494Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa
Auteurs : Antonio Marfella ; Vincenzo Ruocco ; Alba Capobianco ; Mario Perna ; Giovanni Santelli ; Giovanni Frigione ; Sebastian K. Kyalwazi ; Roy D. Mugerwa ; David Serwadda ; Elke Beth-Giraldo ; Gaetano GiraldoSource :
- European Journal of Cancer and Clinical Oncology [ 0277-5379 ] ; 1989.
English descriptors
- Teeft :
- African kaposi, Correlation coefficient, Immunodeficiency, Immunodeficiency syndrome, Kaposi, Lancet, Macrophage, Neopterin, Neopterin levels, Opportunistic, Opportunistic infections, Progressive kaposi, Regressive, Regressive kaposi, Sarcoma, Sarcoma patients, Sarcoma sera, Sars coma, Tryptophan, Urinary neopterin, Virus replication.
Abstract
Abstract: The presence of circulating alpha-interferon and neopterin was investigated in sera of 47 patients affected by African Kaposi's sarcoma, both HIV-seropositive (13 patients) and HIV-seronegative (34 patients). For comparison, analyses were also performed in 20 HIV-seropositive symptomatic African subjects as well as in 20 African and 20 Italian healthy individuals.Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (P < 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (27 patients) than in regressive Kaposi's sarcoma (20 patients) (P < 0.001). A significant correlation between alpha-interferon and neopterin was observed (r = 0.57; P < 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (P < 0.05).It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.
Url:
DOI: 10.1016/0277-5379(89)90407-0
Links to Exploration step
ISTEX:024C30C93791DAC932226532DF654E4B20756521Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title><author><name sortKey="Marfella, Antonio" sort="Marfella, Antonio" uniqKey="Marfella A" first="Antonio" last="Marfella">Antonio Marfella</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ruocco, Vincenzo" sort="Ruocco, Vincenzo" uniqKey="Ruocco V" first="Vincenzo" last="Ruocco">Vincenzo Ruocco</name><affiliation><mods:affiliation>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Capobianco, Alba" sort="Capobianco, Alba" uniqKey="Capobianco A" first="Alba" last="Capobianco">Alba Capobianco</name><affiliation><mods:affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</mods:affiliation></affiliation></author><author><name sortKey="Perna, Mario" sort="Perna, Mario" uniqKey="Perna M" first="Mario" last="Perna">Mario Perna</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Santelli, Giovanni" sort="Santelli, Giovanni" uniqKey="Santelli G" first="Giovanni" last="Santelli">Giovanni Santelli</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Frigione, Giovanni" sort="Frigione, Giovanni" uniqKey="Frigione G" first="Giovanni" last="Frigione">Giovanni Frigione</name><affiliation><mods:affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</mods:affiliation></affiliation></author><author><name sortKey="Kyalwazi, Sebastian K" sort="Kyalwazi, Sebastian K" uniqKey="Kyalwazi S" first="Sebastian K." last="Kyalwazi">Sebastian K. Kyalwazi</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Mugerwa, Roy D" sort="Mugerwa, Roy D" uniqKey="Mugerwa R" first="Roy D." last="Mugerwa">Roy D. Mugerwa</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Serwadda, David" sort="Serwadda, David" uniqKey="Serwadda D" first="David" last="Serwadda">David Serwadda</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Beth Giraldo, Elke" sort="Beth Giraldo, Elke" uniqKey="Beth Giraldo E" first="Elke" last="Beth-Giraldo">Elke Beth-Giraldo</name><affiliation><mods:affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Giraldo, Gaetano" sort="Giraldo, Gaetano" uniqKey="Giraldo G" first="Gaetano" last="Giraldo">Gaetano Giraldo</name><affiliation><mods:affiliation>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:024C30C93791DAC932226532DF654E4B20756521</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1016/0277-5379(89)90407-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000493</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000493</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title><author><name sortKey="Marfella, Antonio" sort="Marfella, Antonio" uniqKey="Marfella A" first="Antonio" last="Marfella">Antonio Marfella</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ruocco, Vincenzo" sort="Ruocco, Vincenzo" uniqKey="Ruocco V" first="Vincenzo" last="Ruocco">Vincenzo Ruocco</name><affiliation><mods:affiliation>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Capobianco, Alba" sort="Capobianco, Alba" uniqKey="Capobianco A" first="Alba" last="Capobianco">Alba Capobianco</name><affiliation><mods:affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</mods:affiliation></affiliation></author><author><name sortKey="Perna, Mario" sort="Perna, Mario" uniqKey="Perna M" first="Mario" last="Perna">Mario Perna</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Santelli, Giovanni" sort="Santelli, Giovanni" uniqKey="Santelli G" first="Giovanni" last="Santelli">Giovanni Santelli</name><affiliation><mods:affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Frigione, Giovanni" sort="Frigione, Giovanni" uniqKey="Frigione G" first="Giovanni" last="Frigione">Giovanni Frigione</name><affiliation><mods:affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</mods:affiliation></affiliation></author><author><name sortKey="Kyalwazi, Sebastian K" sort="Kyalwazi, Sebastian K" uniqKey="Kyalwazi S" first="Sebastian K." last="Kyalwazi">Sebastian K. Kyalwazi</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Mugerwa, Roy D" sort="Mugerwa, Roy D" uniqKey="Mugerwa R" first="Roy D." last="Mugerwa">Roy D. Mugerwa</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Serwadda, David" sort="Serwadda, David" uniqKey="Serwadda D" first="David" last="Serwadda">David Serwadda</name><affiliation><mods:affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</mods:affiliation></affiliation></author><author><name sortKey="Beth Giraldo, Elke" sort="Beth Giraldo, Elke" uniqKey="Beth Giraldo E" first="Elke" last="Beth-Giraldo">Elke Beth-Giraldo</name><affiliation><mods:affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</mods:affiliation></affiliation></author><author><name sortKey="Giraldo, Gaetano" sort="Giraldo, Gaetano" uniqKey="Giraldo G" first="Gaetano" last="Giraldo">Gaetano Giraldo</name><affiliation><mods:affiliation>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer and Clinical Oncology</title><title level="j" type="abbrev">EJCCO</title><idno type="ISSN">0277-5379</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1989">1989</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1145">1145</biblScope><biblScope unit="page" to="1150">1150</biblScope></imprint><idno type="ISSN">0277-5379</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-5379</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>African kaposi</term><term>Correlation coefficient</term><term>Immunodeficiency</term><term>Immunodeficiency syndrome</term><term>Kaposi</term><term>Lancet</term><term>Macrophage</term><term>Neopterin</term><term>Neopterin levels</term><term>Opportunistic</term><term>Opportunistic infections</term><term>Progressive kaposi</term><term>Regressive</term><term>Regressive kaposi</term><term>Sarcoma</term><term>Sarcoma patients</term><term>Sarcoma sera</term><term>Sars coma</term><term>Tryptophan</term><term>Urinary neopterin</term><term>Virus replication</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The presence of circulating alpha-interferon and neopterin was investigated in sera of 47 patients affected by African Kaposi's sarcoma, both HIV-seropositive (13 patients) and HIV-seronegative (34 patients). For comparison, analyses were also performed in 20 HIV-seropositive symptomatic African subjects as well as in 20 African and 20 Italian healthy individuals.Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (P < 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (27 patients) than in regressive Kaposi's sarcoma (20 patients) (P < 0.001). A significant correlation between alpha-interferon and neopterin was observed (r = 0.57; P < 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (P < 0.05).It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>sarcoma</json:string><json:string>kaposi</json:string><json:string>neopterin</json:string><json:string>sarcoma patients</json:string><json:string>neopterin levels</json:string><json:string>african kaposi</json:string><json:string>macrophage</json:string><json:string>immunodeficiency</json:string><json:string>lancet</json:string><json:string>regressive</json:string><json:string>regressive kaposi</json:string><json:string>tryptophan</json:string><json:string>correlation coefficient</json:string><json:string>progressive kaposi</json:string><json:string>opportunistic</json:string><json:string>sarcoma sera</json:string><json:string>sars coma</json:string><json:string>virus replication</json:string><json:string>opportunistic infections</json:string><json:string>immunodeficiency syndrome</json:string><json:string>urinary neopterin</json:string></teeft></keywords><author><json:item><name>Antonio Marfella</name><affiliations><json:string>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</json:string></affiliations></json:item><json:item><name>Vincenzo Ruocco</name><affiliations><json:string>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</json:string></affiliations></json:item><json:item><name>Alba Capobianco</name><affiliations><json:string>Ospedale S. Carlo, USL 2, Potenza, Italy</json:string></affiliations></json:item><json:item><name>Mario Perna</name><affiliations><json:string>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</json:string></affiliations></json:item><json:item><name>Giovanni Santelli</name><affiliations><json:string>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</json:string></affiliations></json:item><json:item><name>Giovanni Frigione</name><affiliations><json:string>Ospedale S. Carlo, USL 2, Potenza, Italy</json:string></affiliations></json:item><json:item><name>Sebastian K. Kyalwazi</name><affiliations><json:string>Mulago Hospital, Makerere University, Kampala, Uganda</json:string></affiliations></json:item><json:item><name>Roy D. Mugerwa</name><affiliations><json:string>Mulago Hospital, Makerere University, Kampala, Uganda</json:string></affiliations></json:item><json:item><name>David Serwadda</name><affiliations><json:string>Mulago Hospital, Makerere University, Kampala, Uganda</json:string></affiliations></json:item><json:item><name>Elke Beth-Giraldo</name><affiliations><json:string>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</json:string></affiliations></json:item><json:item><name>Gaetano Giraldo</name><affiliations><json:string>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</json:string><json:string>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>AIDS = acquired immunodeficiency syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HIV = human immunodeficiency virus type 1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ARC = AIDS related complex</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>LAS = systemic lymphoadenopathy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CMV = cytomegalovirus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>EBV = Epstein-Barr virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HSV 2 = herpes virus type 2</value></json:item></subject><arkIstex>ark:/67375/6H6-0Q2QG76Z-P</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: The presence of circulating alpha-interferon and neopterin was investigated in sera of 47 patients affected by African Kaposi's sarcoma, both HIV-seropositive (13 patients) and HIV-seronegative (34 patients). For comparison, analyses were also performed in 20 HIV-seropositive symptomatic African subjects as well as in 20 African and 20 Italian healthy individuals.Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (P > 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (27 patients) than in regressive Kaposi's sarcoma (20 patients) (P > 0.001). A significant correlation between alpha-interferon and neopterin was observed (r = 0.57; P > 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (P > 0.05).It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>149</abstractWordCount><abstractCharCount>1138</abstractCharCount><keywordCount>7</keywordCount><score>6.38</score><pdfWordCount>2592</pdfWordCount><pdfCharCount>19997</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>576 x 828 pts</pdfPageSize></qualityIndicators><title>Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title><pmid><json:string>2767104</json:string></pmid><pii><json:string>0277-5379(89)90407-0</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Proc Natl Acad Sci USA</title><language><json:string>unknown</json:string></language><volume>83</volume><pages><first>7935</first><last>7937</last></pages></serie><host><title>European Journal of Cancer and Clinical Oncology</title><language><json:string>unknown</json:string></language><publicationDate>1989</publicationDate><issn><json:string>0277-5379</json:string></issn><pii><json:string>S0277-5379(00)X0074-0</json:string></pii><volume>25</volume><issue>8</issue><pages><first>1145</first><last>1150</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1975</json:string><json:string>1971</json:string><json:string>1989</json:string></date><geogName></geogName><orgName><json:string>Italy , Abstract-The</json:string><json:string>National Cancer Institute</json:string><json:string>Henning Berlin Laboratories, Berlin</json:string><json:string>Ministry of Health</json:string><json:string>Celltech</json:string><json:string>Hospital, Cancer Institute</json:string><json:string>University of Naples, Italy</json:string><json:string>Makerere University</json:string><json:string>Division of Viral Oncology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>M. Semmola</json:string><json:string>G. Pascale</json:string><json:string>F.R.G. Results</json:string><json:string>Viral Oncology</json:string><json:string>O.Ol</json:string><json:string>Via M. Semmola</json:string><json:string>A. Marfella</json:string><json:string>S. Carlo</json:string><json:string>G. Giraldo</json:string></persName><placeName><json:string>Naples</json:string><json:string>Uganda</json:string><json:string>Europe</json:string><json:string>Potenza</json:string><json:string>Kampala</json:string><json:string>Italy</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[6]</json:string><json:string>[33]</json:string><json:string>[8]</json:string><json:string>[28]</json:string><json:string>[32]</json:string><json:string>[27]</json:string><json:string>[3]</json:string><json:string>[31]</json:string><json:string>[5]</json:string><json:string>[26]</json:string><json:string>Krigel et al. [9]</json:string><json:string>[7]</json:string><json:string>[25]</json:string><json:string>[2]</json:string><json:string>A. Marfella et al. 1148</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-0Q2QG76Z-P</json:string></ark><categories><wos></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1016/0277-5379(89)90407-0</json:string></doi><id>024C30C93791DAC932226532DF654E4B20756521</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1989</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Supported in part by grants of the Italian Association for Cancer Research (AIRC) and of the Italian Ministry of Health.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title><author xml:id="author-0000"><persName><forename type="first">Antonio</forename><surname>Marfella</surname></persName><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Vincenzo</forename><surname>Ruocco</surname></persName><affiliation>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Alba</forename><surname>Capobianco</surname></persName><affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Mario</forename><surname>Perna</surname></persName><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Giovanni</forename><surname>Santelli</surname></persName><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Giovanni</forename><surname>Frigione</surname></persName><affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Sebastian K.</forename><surname>Kyalwazi</surname></persName><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Roy D.</forename><surname>Mugerwa</surname></persName><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation></author><author xml:id="author-0008"><persName><forename type="first">David</forename><surname>Serwadda</surname></persName><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Elke</forename><surname>Beth-Giraldo</surname></persName><affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Gaetano</forename><surname>Giraldo</surname></persName><affiliation>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</affiliation><affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</affiliation></author><idno type="istex">024C30C93791DAC932226532DF654E4B20756521</idno><idno type="ark">ark:/67375/6H6-0Q2QG76Z-P</idno><idno type="DOI">10.1016/0277-5379(89)90407-0</idno><idno type="PII">0277-5379(89)90407-0</idno></analytic><monogr><title level="j">European Journal of Cancer and Clinical Oncology</title><title level="j" type="abbrev">EJCCO</title><idno type="pISSN">0277-5379</idno><idno type="PII">S0277-5379(00)X0074-0</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1989"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1145">1145</biblScope><biblScope unit="page" to="1150">1150</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The presence of circulating alpha-interferon and neopterin was investigated in sera of 47 patients affected by African Kaposi's sarcoma, both HIV-seropositive (13 patients) and HIV-seronegative (34 patients). For comparison, analyses were also performed in 20 HIV-seropositive symptomatic African subjects as well as in 20 African and 20 Italian healthy individuals.Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (P < 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (27 patients) than in regressive Kaposi's sarcoma (20 patients) (P < 0.001). A significant correlation between alpha-interferon and neopterin was observed (r = 0.57; P < 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (P < 0.05).It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.</p></abstract><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>AIDS = acquired immunodeficiency syndrome</term></item><item><term>HIV = human immunodeficiency virus type 1</term></item><item><term>ARC = AIDS related complex</term></item><item><term>LAS = systemic lymphoadenopathy</term></item><item><term>CMV = cytomegalovirus</term></item><item><term>EBV = Epstein-Barr virus</term></item><item><term>HSV 2 = herpes virus type 2</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>EJCCO</jid><aid>89904070</aid><ce:pii>0277-5379(89)90407-0</ce:pii><ce:doi>10.1016/0277-5379(89)90407-0</ce:doi><ce:copyright type="unknown" year="1989"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Supported in part by grants of the Italian Association for Cancer Research (AIRC) and of the Italian Ministry of Health.</ce:note-para></ce:article-footnote><ce:title>Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</ce:title><ce:author-group><ce:author><ce:given-name>Antonio</ce:given-name><ce:surname>Marfella</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Vincenzo</ce:given-name><ce:surname>Ruocco</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Alba</ce:given-name><ce:surname>Capobianco</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Mario</ce:given-name><ce:surname>Perna</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Giovanni</ce:given-name><ce:surname>Santelli</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Giovanni</ce:given-name><ce:surname>Frigione</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Sebastian K.</ce:given-name><ce:surname>Kyalwazi</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Roy D.</ce:given-name><ce:surname>Mugerwa</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>David</ce:given-name><ce:surname>Serwadda</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Elke</ce:given-name><ce:surname>Beth-Giraldo</ce:surname><ce:cross-ref refid="AFF5"><ce:sup>∥</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Gaetano</ce:given-name><ce:surname>Giraldo</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF5"><ce:sup>∥</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>†</ce:label><ce:textfn>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>‡</ce:label><ce:textfn>Ospedale S. Carlo, USL 2, Potenza, Italy</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>§</ce:label><ce:textfn>Mulago Hospital, Makerere University, Kampala, Uganda</ce:textfn></ce:affiliation><ce:affiliation id="AFF5"><ce:label>∥</ce:label><ce:textfn>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="1" month="3" year="1989"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The presence of circulating alpha-interferon and neopterin was investigated in sera of <ce:italic>47</ce:italic> patients affected by African Kaposi's sarcoma, both HIV-seropositive (<ce:italic>13</ce:italic> patients) and HIV-seronegative (<ce:italic>34</ce:italic> patients). For comparison, analyses were also performed in <ce:italic>20</ce:italic> HIV-seropositive symptomatic African subjects as well as in <ce:italic>20</ce:italic> African and <ce:italic>20</ce:italic> Italian healthy individuals.</ce:simple-para><ce:simple-para>Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (<ce:italic>P</ce:italic> < 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (<ce:italic>27</ce:italic> patients) than in regressive Kaposi's sarcoma (<ce:italic>20</ce:italic> patients) (<ce:italic>P</ce:italic> < 0.001). A significant correlation between alpha-interferon and neopterin was observed (<ce:italic>r</ce:italic> = 0.57; <ce:italic>P</ce:italic> < 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (<ce:italic>P</ce:italic> < 0.05).</ce:simple-para><ce:simple-para>It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>AIDS = acquired immunodeficiency syndrome</ce:text></ce:keyword><ce:keyword><ce:text>HIV = human immunodeficiency virus type 1</ce:text></ce:keyword><ce:keyword><ce:text>ARC = AIDS related complex</ce:text></ce:keyword><ce:keyword><ce:text>LAS = systemic lymphoadenopathy</ce:text></ce:keyword><ce:keyword><ce:text>CMV = cytomegalovirus</ce:text></ce:keyword><ce:keyword><ce:text>EBV = Epstein-Barr virus</ce:text></ce:keyword><ce:keyword><ce:text>HSV 2 = herpes virus type 2</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa</title></titleInfo><name type="personal"><namePart type="given">Antonio</namePart><namePart type="family">Marfella</namePart><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vincenzo</namePart><namePart type="family">Ruocco</namePart><affiliation>Dermatologic Clinic, I Faculty of Medicine, University of Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alba</namePart><namePart type="family">Capobianco</namePart><affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mario</namePart><namePart type="family">Perna</namePart><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Santelli</namePart><affiliation>Laboratory of Clinical Pathology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, via M. Semmola, 80131, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Frigione</namePart><affiliation>Ospedale S. Carlo, USL 2, Potenza, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sebastian K.</namePart><namePart type="family">Kyalwazi</namePart><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roy D.</namePart><namePart type="family">Mugerwa</namePart><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Serwadda</namePart><affiliation>Mulago Hospital, Makerere University, Kampala, Uganda</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elke</namePart><namePart type="family">Beth-Giraldo</namePart><affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gaetano</namePart><namePart type="family">Giraldo</namePart><affiliation>Scientific correspondence to: Prof. G. Giraldo, Division of Viral Oncology, Istituto per lo Studio e la Cura dei Tumori ‘Fondaz. Sen. G. Pascale’, Via M. Semmola, 80131, Naples, Italy.</affiliation><affiliation>Division of Viral Oncology, National Cancer Institute ‘Fondaz. Sen. G. Pascale’, Naples, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1989</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The presence of circulating alpha-interferon and neopterin was investigated in sera of 47 patients affected by African Kaposi's sarcoma, both HIV-seropositive (13 patients) and HIV-seronegative (34 patients). For comparison, analyses were also performed in 20 HIV-seropositive symptomatic African subjects as well as in 20 African and 20 Italian healthy individuals.Alpha-interferon and neopterin levels appeared significantly higher in comparison with healthy control groups (P < 0.001) but not with HIV-seropositive African individuals without Kaposi's sarcoma. Moreover, alpha-interferon and neopterin levels were significantly higher in progressive Kaposi's sarcoma (27 patients) than in regressive Kaposi's sarcoma (20 patients) (P < 0.001). A significant correlation between alpha-interferon and neopterin was observed (r = 0.57; P < 0.01). Furthermore, alpha-interferon levels of HIV-seropositive Kaposi's sarcoma patients resulted significantly higher in comparison with the seronegative ones (P < 0.05).It is concluded that alpha-interferon and neopterin may be reliable prognostic markers in Kaposi's sarcoma patients.</abstract><note>Supported in part by grants of the Italian Association for Cancer Research (AIRC) and of the Italian Ministry of Health.</note><subject><genre>Abbreviations</genre><topic>AIDS = acquired immunodeficiency syndrome</topic><topic>HIV = human immunodeficiency virus type 1</topic><topic>ARC = AIDS related complex</topic><topic>LAS = systemic lymphoadenopathy</topic><topic>CMV = cytomegalovirus</topic><topic>EBV = Epstein-Barr virus</topic><topic>HSV 2 = herpes virus type 2</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Cancer and Clinical Oncology</title></titleInfo><titleInfo type="abbreviated"><title>EJCCO</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1989</dateIssued></originInfo><identifier type="ISSN">0277-5379</identifier><identifier type="PII">S0277-5379(00)X0074-0</identifier><part><date>1989</date><detail type="volume"><number>25</number><caption>vol.</caption></detail><detail type="issue"><number>8</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1127</start><end>1261</end></extent><extent unit="pages"><start>1145</start><end>1150</end></extent></part></relatedItem><identifier type="istex">024C30C93791DAC932226532DF654E4B20756521</identifier><identifier type="ark">ark:/67375/6H6-0Q2QG76Z-P</identifier><identifier type="DOI">10.1016/0277-5379(89)90407-0</identifier><identifier type="PII">0277-5379(89)90407-0</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-0Q2QG76Z-P/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000493 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000493 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:024C30C93791DAC932226532DF654E4B20756521
|texte= Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa
}}
| This area was generated with Dilib version V0.6.33. |  |